Clinical Trials Results - National Cancer Institute

Skip to content

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 279 Show results per page	View Search Criteria \| Help With Results


Sort By:	Version:	Format:


1.		Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Treatment				Active				18 and over				Other				POI-02818 NIP-02-005, NCT00131313


2.		German Multicenter Trial for Treatment of Elderly Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Treatment				Active				Over 55				Other				GMALL02 NCT00198978


3.		Trial for Treatment of Adult Patients With Standard Risk Acute Lymphoblastic Leukemia With Chemotherapy and Rituximab

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Treatment				Active				15 to 65				Other				GMALL03 NCT00199004


4.		Trial for the Treatment of Newly Diagnosed Mature B-Cell Acute Lymphoblastic Leukemia (B-ALL), Burkitt's Non-Hodgkin's Lymphoma (NHL) and Other High-Grade Lymphoma in Adults

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Treatment				Active				Over 15				Other				GMALL05 NCT00199082


5.		Treatment of Good Prognosis, BCL-6 Negative Diffuse Large Cell Lymphoma With CHOP-R in Patients < 61 Years Old.

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Treatment				Active				15 to 60				Other				Hemato INCAN 01/2007 NCT00429065


6.		Treatment With Chemotherapy Plus Rituximab and Highly Active Antiretroviral Therapy in Patients With Diffuse Large B Cell Lymphoma and Infection With the Human Immunodeficiency Virus (HIV)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Treatment				Active				18 to 70				Other				2006-003750-23 LINFOTARGAM, NCT00466258


7.		Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma in Adults

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Treatment				Active				18 and over				Other				HEMOS ALL1105 NCT00797810


8.		Lumiliximab With Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Active				18 and over				Pharmaceutical / Industry				152CL201 NCT00391066

Last Modified: 11/11/2008 First Published: 8/1/1997


9.		Phase III Study of Early High-Dose Chemoradiotherapy and Autologous Peripheral Blood Stem Cell Transplantation Versus Conventional Dose Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Patients with Intermediate- or High-Grade Non-Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				15 to 65				NCI				SWOG-S9704 CAN-NCIC-LY11, CALGB-59903, ECOG-S9704, S9704, NCT00004031, LY11

Last Modified: 3/14/2008 First Published: 3/1/2001


10.		Phase III Randomized Study of Sequential Chemotherapy With or Without Rituximab Followed By Ablative Chemotherapy and Autologous Peripheral Blood Stem Cell Transplantation in Patients With Relapsed, CD20 Positive, Aggressive B-Cell Non-Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 to 65				Other				CKTO-2000-06 HOVON-44, HOVON-44/CKVO-2000-06, EU-20042, ISRCTN95614846, NCT00012051

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute